Genentech® Transplant Access Services (GTAS) offers a range of access and reimbursement support for your patients and practice.

Coverage and reimbursement services


(valganciclovir hydrochloride)


(mycophenolate mofetil)

Full benefits investigation

Prior authorization assistance

Appeals support

Patient assistance programs

Who We Help

Patient Situation

What We Offer

Patient-Specific Solutions

Transplant patients with private (commercial) insurance

Valcyte® and CellCept® $15 Co-pay Cards*

  • Eligible patients pay $15 per monthly co-pay
  • No income requirements
  • Both co-pay cards offer an annual benefit limit up to $10,000

Please see full terms and conditions by visiting or

Transplant patients with either private (commercial) or public insurance

Referrals to co-pay assistance foundations

GTAS offers referrals to independent co-pay assistance foundations for eligible patients who are commercially or publicly insured, including those covered by Medicare and Medicaid.

Transplant patients who are uninsured, rendered uninsured by payer denial, or underinsured

Genentech® Access to Care Foundation (GATCF)

GATCF helps eligible patients who meet specific criteria receive Valcyte or CellCept free of charge.

GATCF provides free medicine to eligible patients who are uninsured, rendered uninsured by payer denial, or underinsured. To qualify, patients must meet specific criteria.


* In order to qualify for the benefits of the Valcyte® $15 Co-pay Card and/or the CellCept® $15 Co-pay Card, the patient may be required to pay certain out-of-pocket expenses for each treatment. Patients must also be taking the medication for an FDA-approved indication. Patients using Medicare, Medicaid, or any other government-funded program to pay for their medications are not eligible. Patients who start utilizing their government coverage during their enrollment period will no longer be eligible for the program. Once enrolled, this Co-pay Card program will not honor claims with date of service or medication dispensing that precede program enrollment by more than 120 days. Participating patients, pharmacies, physician offices, and hospitals are responsible for reporting the receipt of all Co-pay Card benefits or reimbursement received, to any insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the Co-pay Card program. This card is not health insurance or a benefit plan. The patient or his/her guardian must be 18 years or older to receive Co-pay Card benefits. This Co-pay Card program is void if the card is reproduced and where prohibited by law. It is only valid for Genentech products and only valid in the U.S. and Puerto Rico. For Massachusetts’ residents, the Co-pay Card is not valid for any prescription drug that has an AB-rated generic equivalent as determined by the United States Food and Drug Administration. The Co-pay Card program expires within 12 months from enrollment. Genentech, Inc. reserves the right to rescind, revoke, or amend the program without notice at any time. Patient, guardian, pharmacist, prescriber, and any other person using the Co-pay Card agree not to seek reimbursement for all or any part of the benefit received by the recipient through the offer. Additional Terms & Conditions apply. Please visit or for the full list of Terms & Conditions.

The completion and submission of coverage- or reimbursement-related documentation are the responsibility of the patient and healthcare provider. Genentech makes no representation or guarantee concerning coverage or reimbursement for any service or item.

Genentech and GTAS do not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from GTAS. The foundations to which we refer patients are not exhaustive or indicative of Genentech's endorsement or financial support. There may be other foundations to support the patient's disease state.


Please see both Co-pay Cards for more terms and conditions.


If you have any questions about which coverage and reimbursement or patient assistance program is best for your transplant patient,
call 1-888-754-7651.

Our representatives are an excellent starting point to discuss the assistance options available.



(valganciclovir hydrochloride)
Indications and Important Safety Information


Adult Patients:
Valcyte® (valganciclovir hydrochloride) is indicated for the treatment of cytomegalovirus (CMV) disease in kidney, heart, and kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]).

Pediatric Patients:
Valcyte is indicated for the prevention of CMV disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk.

Adult patients should use Valcyte tablets, not Valcyte for oral solution. Valcyte for oral solution (50 mg/mL) must be prepared by the pharmacist prior to dispensing to the patient.



  • Hematologic Toxicity: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow failure, and aplastic anemia have been reported in patients treated with Valcyte
  • Impairment of Fertility: Based on animal data, Valcyte may cause temporary or permanent inhibition of spermatogenesis
  • Fetal Toxicity: Based on animal data, Valcyte has the potential to cause birth defects in humans
  • Mutagenesis and Carcinogenesis: Based on animal data, Valcyte has the potential to cause cancers in humans


Valcyte is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (eg, anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation.


  • Hematologic toxicity: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, and aplastic anemia have occurred with the use of Valcyte or ganciclovir. Avoid Valcyte use if absolute neutrophil count is less than 500 cells/µL, platelet count is less than 25,000/µL, or hemoglobin is less than 8 g/dL. Use with caution in pre-existing cytopenias and when receiving myelosuppressive drugs or irradiation. Monitor with frequent testing of platelet and complete blood counts. In patients with severe leukopenia, neutropenia, anemia and/or thrombocytopenia, treatment with hematopoietic growth factors and or the interruption of therapy is recommended. Patients with low baseline platelet counts (<100,000 /µL) have an increased risk of developing thrombocytopenia. Patients with iatrogenic immunosuppression due to treatment with immunosuppressive drugs are at greater risk of thrombocytopenia than patients with AIDS. Severe thrombocytopenia may be associated with potentially life-threatening bleeding.
  • Impairment of fertility: Based on animal studies, Valcyte may cause temporary or permanent inhibition of spermatogenesis. Advise patients that fertility may be impaired with use of Valcyte.
  • Fetal toxicity: Based on animal studies, Valcyte may cause fetal harm. Pregnancy should be avoided in female patients taking Valcyte and in females with male partners taking Valcyte. Females of reproductive potential should be advised of the potential risk to the fetus and use effective contraception during and following treatment and males should practice barrier contraception during and following treatment.
  • Mutagenicity and carcinogenicity: Based on animal studies, Valcyte is potentially mutagenic and carcinogenic.
  • Acute renal failure: Acute renal failure may occur in elderly patients (with or without reduced renal function), patients who receive concomitant nephrotoxic drugs, or inadequately hydrated patients. Use with caution in elderly patients or those taking nephrotoxic drugs, reduce dosage in patients with renal impairment, and monitor renal function. Adequate hydration should be maintained for all patients.
  • Cross hypersensitivity: Due to the similarity of the chemical structure of ganciclovir and that of aciclovir and valaciclovir, a cross-hypersensitivity reaction between these drugs is possible. Caution should therefore be used when prescribing Valcyte to patients with known hypersensitivity to aciclovir or penciclovir, or to their prodrugs, valaciclovir or famciclovir.
  • Potential drug interactions: Toxicity may be enhanced when Valcyte is co-administered with other drugs known to be myelosuppressive or associated with renal impairment. These drugs should only be considered for concomitant use with valganciclovir if the potential benefits outweigh the potential risks.
    • Zidovudine: Potential to cause neutropenia and anemia. Monitor with frequent tests of white blood cell counts with differential and hemoglobin levels.
    • Probenecid: May increase ganciclovir levels. Monitor for evidence of ganciclovir toxicity.
    • Mycophenolate mofetil (MMF): Based on increased risk, patients should be monitored for hematological and renal toxicity.
    • Didanosine: May increase didanosine concentrations. Monitor for didanosine toxicity (eg, pancreatitis).


Adult Patients: The most common adverse reactions and laboratory abnormalities reported in at least one indication by ≥20% of adult patients are diarrhea, pyrexia, nausea, tremor, neutropenia, anemia, graft rejection, thrombocytopenia, and vomiting.

Pediatric Patients: The most common adverse reactions and laboratory abnormalities reported in ≥20% of pediatric solid organ transplant recipients are diarrhea, pyrexia, hypertension, upper respiratory tract infection, urinary tract infection, vomiting, neutropenia, leukopenia, and headache.

Please click here for Valcyte full Prescribing Information, including Boxed WARNINGS, for additional Important Safety Information.


(mycophenolate mofetil)
Indication and Important Safety Information


CellCept® (mycophenolate mofetil) is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids.

CellCept Intravenous is an alternative dosage form to CellCept capsules, tablets, and oral suspension. CellCept Intravenous should be administered within 24 hours following transplantation. CellCept Intravenous can be administered for up to 14 days; patients should be switched to oral CellCept as soon as they can tolerate oral medication.



Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Females of reproductive potential (FRP) must be counseled regarding pregnancy prevention and planning.

Immunosuppression may lead to increased susceptibility to infection and possible development of lymphoma. Only physicians experienced in immunosuppressive therapy and management of renal, cardiac, or hepatic transplant patients should prescribe CellCept. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.


CellCept is contraindicated in patients with a hypersensitivity to mycophenolate mofetil, mycophenolic acid or any component of the drug product. CellCept Intravenous is contraindicated in patients who are allergic to Polysorbate 80 (TWEEN).


  • Pregnancy category D: Mycophenolate mofetil (MMF) can cause fetal harm when administered to a pregnant female. Use of MMF during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations, especially external ear and other facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, kidney, and nervous system. Females of reproductive potential must be made aware of the increased risk of first trimester pregnancy loss and congenital malformations and must be counseled regarding pregnancy prevention and planning.
  • Patients receiving immunosuppressive regimens involving combinations of drugs, including CellCept, are at increased risk of developing lymphomas and other malignancies, particularly of the skin.
  • CellCept has been administered in combination with the following agents in clinical trials: antithymocyte globulin, OKT3, cyclosporine, and corticosteroids. The efficacy and safety in combination with other immunosuppressive agents have not been determined.
  • Patients receiving immunosuppressants, including CellCept, are at increased risk of developing bacterial, fungal, protozoal and new or reactivated viral infections, including opportunistic infections. These infections may lead to serious, including fatal outcomes. Because of the danger of oversuppression of the immune system which can increase susceptibility to infection, combination immunosuppressant therapy should be used with caution.
  • Polyomavirus associated nephropathy (PVAN), JC virus associated progressive multifocal leukoencephalopathy (PML), cytomegalovirus (CMV) infections, reactivation of hepatitis B (HBV) or hepatitis C (HCV) have been reported in patients treated with immunosuppressants, including CellCept. Reduction in immunosuppression should be considered for patients who develop evidence of new or reactivated viral infections. Physicians should also consider the risk that reduced immunosuppression represents to the functioning allograft.

    PVAN, especially due to BK virus infection, is associated with serious outcomes, including deteriorating renal function and renal graft loss. Patient monitoring may help detect patients at risk for PVAN.

    PML, which is sometimes fatal, commonly presents with hemiparesis, apathy, confusion, cognitive deficiencies, and ataxia. Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function. In immunosuppressed patients, physicians should consider PML in the differential diagnosis in patients reporting neurological symptoms and consultation with a neurologist should be considered as clinically indicated.

    The risk of CMV viremia and CMV disease is highest among transplant recipients seronegative for CMV at time of transplant who receive a graft from a CMV seropositive donor. Therapeutic approaches to limiting CMV disease exist and should be routinely provided. Patient monitoring may help detect patients at risk for CMV disease.

    Viral reactivation has been reported in patients infected with HBV or HCV. Monitoring infected patients for clinical and laboratory signs of active HBV or HCV infection is recommended.
  • Monitor patients for neutropenia that has been observed most frequently in the period of 31 to 180 days posttransplant. If neutropenia develops [absolute neutrophil count (ANC) <1.3 x 10³/µL], interrupt or reduce dosing with CellCept, perform appropriate diagnostic tests and manage patient appropriately. Severe neutropenia (ANC <0.5 x 10³/µL) developed in up to 2.0% of renal, up to 2.8% of cardiac, and up to 3.6% of hepatic transplant patients receiving CellCept 3 g daily. Instruct patients to report immediately any evidence of infection, unexpected bruising, bleeding, or any other manifestation of bone marrow depression.
  • Cases of pure red cell aplasia (PRCA) have been reported in patients treated with CellCept in combination with other immunosuppressive agents. The mechanism for CellCept induced PRCA and the relative contribution of other immunosuppressants and their combinations in an immunosuppression regimen are unknown. In some cases, PRCA was found to be reversible with dose reduction or cessation of CellCept. In transplant patients, however, reduced immunosuppression may place the graft at risk.


  • Females of reproductive potential (including pubertal girls and perimenopausal women) must be made aware of the increased risk of first trimester pregnancy loss and congenital malformations and must be counseled regarding pregnancy prevention and planning.
    • Pregnancy Testing: females of reproductive potential should have a serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL immediately before starting CellCept. Another pregnancy test with the same sensitivity should be done 8 to 10 days later. Repeat pregnancy tests should be performed during routine follow-up visits. In the event of a positive pregnancy test, females should be counseled with regard to whether the maternal benefits of mycophenolate treatment may outweigh the risks to the fetus in certain situations, please report the pregnancy to Mycophenolate Pregnancy Registry (1-800-617-8191).
    • Contraception: Females of reproductive potential taking CellCept must receive contraceptive counseling and use acceptable contraception (see Table 8 of the full Prescribing Information for acceptable contraception methods). Patients must use acceptable birth control during entire CellCept therapy, and for 6 weeks after stopping CellCept, unless the patient chooses abstinence (she chooses to avoid heterosexual intercourse completely).
  • CellCept may be used for cardiac or hepatic transplant patients with severe chronic renal impairment if the potential benefits outweigh the potential risks.
  • In cardiac transplant patients, the overall incidence of opportunistic infections was approximately 10% higher in patients treated with CellCept than in those receiving azathioprine therapy.
  • CellCept should not be administered concomitantly with azathioprine and used with caution when used in the concomitant administration with drugs that interfere with enterohepatic recirculation.
  • CellCept should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT), such as Lesch-Nyhan or Kelley-Seegmiller syndrome.
  • Gastrointestinal bleeding (requiring hospitalization) has been observed.
  • During treatment with CellCept, avoid the use of live attenuated vaccines and advise patients that vaccinations may be less effective.
  • Care should be taken if CellCept Oral Suspension is administered to patients with phenylketonuria.

Adverse Reactions

  • The principal adverse reactions associated with the administration of CellCept include diarrhea, leukopenia, sepsis, vomiting, and there is evidence of a higher frequency of certain types of infections, eg, opportunistic infections (see WARNINGS in full Prescribing Information). The adverse event profile associated with the administration of CellCept Intravenous has been shown to be similar to that observed after administration of oral dosage forms of CellCept. Phlebitis and thrombosis have been reported with intravenous administration. Please refer to the full Prescribing Information for additional ADVERSE REACTIONS.

Please click here for CellCept full Prescribing Information, including Boxed WARNINGS and Medication Guide, for additional Important Safety Information.

Back to Top